http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Ginsenoside Rg1 from Panax ginseng enhances myoblast differentiation and myotube growth
Go, Ga-Yeon,Lee, Sang-Jin,Jo, Ayoung,Lee, Jaecheol,Seo, Dong-Wan,Kang, Jong-Sun,Kim, Si-Kwan,Kim, Su-Nam,Kim, Yong Kee,Bae, Gyu-Un The Korean Society of Ginseng 2017 Journal of Ginseng Research Vol.41 No.4
Background: Ginsenoside Rg1 belongs to protopanaxatriol-type ginsenosides and has diverse pharmacological activities. In this report, we investigated whether Rg1 could upregulate muscular stem cell differentiation and muscle growth. Methods: C2C12 myoblasts, MyoD-transfected 10T1/2 embryonic fibroblasts, and HEK293T cells were treated with Rg1 and differentiated for 2 d, subjected to immunoblotting, immunocytochemistry, or immunoprecipitation. Results: Rg1 activated promyogenic kinases, p38MAPK (mitogen-activated protein kinase) and Akt signaling, that in turn promote the heterodimerization with MyoD and E proteins, resulting in enhancing myogenic differentiation. Through the activation of Akt/mammalian target of rapamycin pathway, Rg1 induced myotube growth and prevented dexamethasone-induced myotube atrophy. Furthermore, Rg1 increased MyoD-dependent myogenic conversion of fibroblast. Conclusion: Rg1 upregulates promyogenic kinases, especially Akt, resulting in improvement of myoblast differentiation and myotube growth.
Kim, Young-eun,Im, Hyo Been,Jung, Un Ho,Park, Ji Chan,Youn, Min Hye,Jeong, Heon-Do,Lee, Dong-Wook,Rhim, Geun Bae,Chun, Dong Hyun,Lee, Ki Bong,Koo, Kee Young Elsevier 2019 Fuel Vol.256 No.-
<P><B>Abstract</B></P> <P>The linear α-olefin 1-octene was produced via the dehydration of 1-octanol over Al<SUB>2</SUB>O<SUB>3</SUB> catalysts. The effect of calcination temperature on the characteristics of an Al<SUB>2</SUB>O<SUB>3</SUB> catalyst and its activity in the dehydration of 1-octanol to 1-octene was investigated. Al<SUB>2</SUB>O<SUB>3</SUB> catalysts calcined at various temperatures (250, 500, 750, 1000 °C) were evaluated at 300–400 °C with a liquid hourly space velocity (LHSV) of 7–56 h<SUP>−1</SUP>. XRD, BET, <SUP>27</SUP>Al-NMR, Py-FTIR, and NH<SUB>3</SUB>-TPD analyses indicated that the calcination temperature affected the crystal phase, surface area, occupancy of the coordinated Al<SUP>3+</SUP> ion, and acidic properties of Al<SUB>2</SUB>O<SUB>3</SUB> catalysts. Upon calcination at temperatures >750 °C, the surface area of Al<SUB>2</SUB>O<SUB>3</SUB> catalysts reduced due to γ-Al<SUB>2</SUB>O<SUB>3</SUB> to θ-Al<SUB>2</SUB>O<SUB>3</SUB> phase transition. The changes in the crystal phase decreased the surface area, which correlated to the acidity of the Al<SUB>2</SUB>O<SUB>3</SUB> catalyst. The distribution of unsaturated Al<SUP>3+</SUP> ions acting as LAS on the catalyst surface increased with increasing calcination temperature, but decreased above 750 °C calcination temperature due to the diminishing surface area. The Al<SUB>2</SUB>O<SUB>3</SUB> catalyst calcined at 500 °C showed the highest 1-octanol conversion in the dehydration of 1-octanol. High 1-octene selectivity was maintained while the isomer ratio decreased at a high LHSV of 56 h<SUP>−1</SUP>.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Linear α-olefin 1-octene produced via dehydration of 1-octanol over Al<SUB>2</SUB>O<SUB>3</SUB> catalyst. </LI> <LI> Changes in crystal phase affected the strong LAS and catalytic activity of Al<SUB>2</SUB>O<SUB>3</SUB>. </LI> <LI> Increased strong LAS improved 1-octanol conversion and 1-octene yield. </LI> <LI> Octene isomers decreased while DOE increased at higher LHSV. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
S-443 : Nilotinib-induced interstitial lung disease
( Un Seok Lee ),( Se Il Go ),( Won Sup Lee ),( Gyeong Won Lee ),( Jung Hun Kang ),( Myung Hee Kang ),( Jeong Hee Lee ),( Hoon Gu Kim ) 대한내과학회 2013 대한내과학회 추계학술대회 Vol.2013 No.1
Nilotinib is a second-generation tyrosine kinase inhibitor active in patients with chronic myeloid leukemia (CML) resistant to imatinib, and has been recently approved for newly diagnosed patients. We present a case of nilotinib-induced interstitial lung disease (ILD). A 67-year-old female patient was initially treated with imatinib for chronic-phase Philadelphia chromosomepositive (Ph+) CML. Imatinib was replaced by nilotinib because of hematological toxicity. The patient had received nilotinib for about 3 years without significant adverse effects. She visited the clinic due to chronic cough; chest X-ray revealed consolidations in both lung fields. Nilotinib-induced ILD was diagnosed based on intensive workup, including lung biopsy. She responded dramatically to corticosteroid therapy. To our knowledge, this is the first reported case of nilotinib-induced ILD in a patient with Ph+ CML. We emphasize that if unexplained lung abnormalities progress in patients receiving nilotinib, physicians should consider this potentially fatal complication in their differential diagnoses.
( Un Seok Lee ),( Won Sup Lee ),( Gyeong Won Lee ),( Jung Hun Kang ),( Myung Hee Kang ),( Se Il Go ),( Anna Lee ),( Hoon-gu Kim ) 대한내과학회 2013 대한내과학회 추계학술대회 Vol.2013 No.1
Monitoring cancer antigen 125 (CA-125) serum levels is very useful for determining how epithelial ovarian cancer is responding to treatment and for predicting a patient`s prognosis after treatment. An increase in CA-125 levels within patients in a remission is a strong predictor of the recurrence of ovarian cancer. However, while CA-125 is best known as a tumor marker for ovarian cancer, it may also be elevated in other various malignancies and in some benign conditions such as peritonitis, pancreatitis, chronic liver diseases, pelvic inflammatory diseases, or endometriosis. We describe herein a case of solitary intra-abdominal tuberculous lymphadenopathy mimicking a local relapse of epithelial ovarian cancer. A 51-year-old woman presented with progressive rise in serum CA-125. She had been diagnosed with advanced epithelial ovarian malignancy and undergone debulking surgery about 4 years ago. She had been given platinum-based adjuvant chemotherapy and achieved complete remission (CR). During regular follow-up in CR, a progressive rise in serum CA-125 was detected. The abdominal computed tomography (CT) showed a cystic mass, 3.6 cm in diameter, located adjacent to the right common iliac artery, suggesting a metastatic lymph node. We had planned second-look operation in settings of suspected focal recurrence of ovarian cancer, supported by evidence of rising CA-125 levels. However, the suspected tuberculous lesion was detected incidentally on preoperative chest CT. The patient had no symptoms and signs associated with tuberculosis (TB) and chest X-ray was also normal. We postponed the planned second-look operation and anti-TB medication was started. Mycobacterium TB was identified on culture of sputum specimens later. During anti-TB medication, the suspected metastatic isolated intra-abdominal lymphadenopathy improved and serum CA-125 level was also normalized. We emphasize here to consider not only the recurrence or progression of ovarian cancer itself but also benign conditions including TB in their differential diagnoses, when serum CA-125 level increases during the follow-up of epithelial ovarian cancer patients.